Pirfenidone regulates pericellular proteolysis in cancer
Loading...
Date
Authors
Advisors/Reviewers
Further Contributors
Contributing Institutions
Publisher
Journal Title
Journal ISSN
Volume Title
Publisher
Quotable link
DOI:
http://dx.doi.org/10.22029/jlupub-5930Abstract
The orally available drug pirfenidone, which is approved for the therapy of idiopathic pulmonary fibrosis is inhibiting the proliferation and migration of lung cancer cells. This effects are partially mediated vie the regulation of the activity of the proteolytic system, especially via PAI-1.